At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.
Patent # | Description |
---|---|
2017/0136030 |
TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE
NON-MEVALONATE PATHWAY Compounds are disclosed that inhibit the methylerythritol cytidyltransferase (IspD) enzyme in the non-mevalonate pathway (MEP pathway), which is present in... |
2017/0136029 |
DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A
MYELINATING CELL FATE The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a ... |
2017/0136028 |
COMPOSITION AND METHOD FOR COMPOUNDED THERAPY A method of compounding a transdermal cream may include grinding one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and one or more nerve... |
2017/0136027 |
Aprepitant Injectable Formulations An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent... |
2017/0136026 |
COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC
AGENTS, AND METHODS OF USE Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates,... |
2017/0136025 |
PHARMACEUTICAL PREPARATION CONTAINING ENTECAVIR AS ACTIVE INGREDIENT, AND
PREPARATION METHOD THEREFOR The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance... |
2017/0136024 |
INHIBITORS OF E1 ACTIVATING ENZYMES This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the... |
2017/0136023 |
QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD
THEREFOR AND APPLICATION THEREOF The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as... |
2017/0136022 |
SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-.alpha.]pyridin-7-yloxy)-3-methylphenyl)-N6-(4- ,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and... |
2017/0136021 |
METHODS AND COMPOSITIONS FOR TREATING ENVELOPED VIRUSES Described are compositions and methods for treating an enveloped virus in a patient in need thereof. Exemplary enveloped viruses are those in the family... |
2017/0136020 |
COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN
SYNDROME Oral dosage forms of osteoclast inhibitors, including some Bruton's tyrosine kinase (BTK) inhibitors, such as dasatinib can be used to treat or alleviate pain... |
2017/0136019 |
sGC STIMULATORS Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds... |
2017/0136018 |
Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK
Inhibitory Activity The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK). |
2017/0136017 |
LIVER X RECEPTOR MODULATORS Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions... |
2017/0136016 |
METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a... |
2017/0136015 |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective... |
2017/0136014 |
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a
JAK-2 Inhibitor Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K)... |
2017/0136013 |
Method of Treating Hand-Foot Syndrome and Symptoms Associated Therewith A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo... |
2017/0136012 |
TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION
DISORDERS USING HEDGEHOG PATHWAY INHIBITORS The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers,... |
2017/0136011 |
TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS
USING HEDGEHOG PATHWAY INHIBITORS The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers,... |
2017/0136010 |
ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING
ORAL SOLID PREPARATION COMPRISING... [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that... |
2017/0136009 |
DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: ##STR00001## It further discloses a... |
2017/0136008 |
OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN
CANCER A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an... |
2017/0136007 |
NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF Disclosed are novel piperazine derivatives that act as agonists of the a7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating... |
2017/0136006 |
METHODS OF MANUFACTURING ORAL DOSAGE FORMS A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a... |
2017/0136005 |
METHODS OF TREATING OPIATE DEPENDENCY AND PREVENTING NON-ORAL OPIATE ABUSE
AMONG OPIATE ADDICTS The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on... |
2017/0136004 |
Opioid Agonist Antagonist Combinations The invention relates a composition comprising an opioid agonist and Compound-1: ##STR00001## |
2017/0136003 |
TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an... |
2017/0136002 |
Composition Containing Apomorphine And A Divalent Metal Cation A composition containing apomorphine and a divalent metal cation, such as, for example, Zn.sup.2+, Ca.sup.2+, or Mg.sup.2+, is disclosed. The composition... |
2017/0136001 |
METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS The invention includes methods, compositions, and kits useful for treating a viral infection by administering ... |
2017/0136000 |
METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering ... |
2017/0135999 |
CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF
EFFECTIVE PLASMA DRUG CONCENTRATIONS The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of... |
2017/0135998 |
Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and
Myelin Disease Therapy Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be... |
2017/0135997 |
TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the... |
2017/0135996 |
PHARMACEUTICAL DEPOT FOR
N-{5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL)-3-FLUORO-4-(PYRIDIN-2-Y-
... A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-y- lmethoxy)benzamide, or a... |
2017/0135995 |
PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS
THEREOF The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in... |
2017/0135994 |
NAMPT INHIBITORS Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is... |
2017/0135993 |
PHARMACEUTICAL COMPOSITION CONTAINING FK506 DERIVATIVE FOR TREATING FUNGAL
INFECTION CAUSED BY GENUS... The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or... |
2017/0135992 |
CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG
SIGNALING PATHWAY The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use... |
2017/0135991 |
NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 ("mPGES-1") inhibitor. Particularly, the... |
2017/0135990 |
PHARMACEUTICAL COMPOSITIONS COMPRISING A 5,5-FUSED HETEROARYLENE
FLAVIVIRIDAE INHIBITOR AND THEIR USE FOR... Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also... |
2017/0135989 |
ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan... |
2017/0135988 |
SYSTEM AND METHOD FOR PREVENTING ALOPECIA Traction alopecia and other disorders related to mechanical pulling on hair are treated or prevented by administering a topical composition comprising an... |
2017/0135987 |
THIOUREYLENE LIQUID COMPOSITIONS The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The... |
2017/0135986 |
STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated... |
2017/0135985 |
THERAPEUTIC/ PREVENTIVE AGENT CONTAINING COUMARIN DERIVATIVE AS ACTIVE
INGREDIENT A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed.... |
2017/0135984 |
INTRANASAL AND TRANSDERMAL ADMINISTRATION OF KAPPA-OPIOID-RECEPTOR
AGONISTS: SALVINORIN A FOR THE TREATMENT OF... Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially... |
2017/0135983 |
COMPOSITION FOR REGULATING BLOOD SUGAR The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold... |
2017/0135982 |
Hydroxyflavanones as Appetite Stimulants The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of... |
2017/0135981 |
Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor... |